536 related articles for article (PubMed ID: 24252749)
1. The VEGF-C/VEGFR3 signaling pathway contributes to resolving chronic skin inflammation by activating lymphatic vessel function.
Hagura A; Asai J; Maruyama K; Takenaka H; Kinoshita S; Katoh N
J Dermatol Sci; 2014 Feb; 73(2):135-41. PubMed ID: 24252749
[TBL] [Abstract][Full Text] [Related]
2. Activation of the VEGFR-3 pathway by VEGF-C attenuates UVB-induced edema formation and skin inflammation by promoting lymphangiogenesis.
Kajiya K; Sawane M; Huggenberger R; Detmar M
J Invest Dermatol; 2009 May; 129(5):1292-8. PubMed ID: 19005491
[TBL] [Abstract][Full Text] [Related]
3. Tumour necrosis factor superfamily member 15 (Tnfsf15) facilitates lymphangiogenesis via up-regulation of Vegfr3 gene expression in lymphatic endothelial cells.
Qin TT; Xu GC; Qi JW; Yang GL; Zhang K; Liu HL; Xu LX; Xiang R; Xiao G; Cao H; Wei Y; Zhang QZ; Li LY
J Pathol; 2015 Nov; 237(3):307-18. PubMed ID: 26096340
[TBL] [Abstract][Full Text] [Related]
4. Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues.
Lohela M; Heloterä H; Haiko P; Dumont DJ; Alitalo K
Am J Pathol; 2008 Dec; 173(6):1891-901. PubMed ID: 18988807
[TBL] [Abstract][Full Text] [Related]
5. Molecular controls of lymphatic VEGFR3 signaling.
Deng Y; Zhang X; Simons M
Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):421-9. PubMed ID: 25524775
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion.
Tacconi C; Correale C; Gandelli A; Spinelli A; Dejana E; D'Alessio S; Danese S
Gastroenterology; 2015 Jun; 148(7):1438-51.e8. PubMed ID: 25754161
[TBL] [Abstract][Full Text] [Related]
7. Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer.
Jeon BH; Jang C; Han J; Kataru RP; Piao L; Jung K; Cha HJ; Schwendener RA; Jang KY; Kim KS; Alitalo K; Koh GY
Cancer Res; 2008 Feb; 68(4):1100-9. PubMed ID: 18281485
[TBL] [Abstract][Full Text] [Related]
8. Induction of lymphangiogenesis through vascular endothelial growth factor-C/vascular endothelial growth factor receptor 3 axis and its correlation with lymph node metastasis in nasopharyngeal carcinoma.
Wakisaka N; Hirota K; Kondo S; Sawada-Kitamura S; Endo K; Murono S; Yoshizaki T
Oral Oncol; 2012 Aug; 48(8):703-8. PubMed ID: 22366442
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation.
Baluk P; Tammela T; Ator E; Lyubynska N; Achen MG; Hicklin DJ; Jeltsch M; Petrova TV; Pytowski B; Stacker SA; Ylä-Herttuala S; Jackson DG; Alitalo K; McDonald DM
J Clin Invest; 2005 Feb; 115(2):247-57. PubMed ID: 15668734
[TBL] [Abstract][Full Text] [Related]
10. TNFR1 mediates TNF-α-induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling.
Ji H; Cao R; Yang Y; Zhang Y; Iwamoto H; Lim S; Nakamura M; Andersson P; Wang J; Sun Y; Dissing S; He X; Yang X; Cao Y
Nat Commun; 2014 Sep; 5():4944. PubMed ID: 25229256
[TBL] [Abstract][Full Text] [Related]
11. Expression of VEGFR-3 and 5'-nase in regenerating lymphatic vessels of the cutaneous wound healing.
Ji RC; Miura M; Qu P; Kato S
Microsc Res Tech; 2004 Jun; 64(3):279-86. PubMed ID: 15452895
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of VEGF ligands and receptors in prostate cancer.
Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
[TBL] [Abstract][Full Text] [Related]
13. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck.
Neuchrist C; Erovic BM; Handisurya A; Fischer MB; Steiner GE; Hollemann D; Gedlicka C; Saaristo A; Burian M
Head Neck; 2003 Jun; 25(6):464-74. PubMed ID: 12784238
[TBL] [Abstract][Full Text] [Related]
15. Targeting lymphatic vessel activation and CCL21 production by vascular endothelial growth factor receptor-3 inhibition has novel immunomodulatory and antiarteriosclerotic effects in cardiac allografts.
Nykänen AI; Sandelin H; Krebs R; Keränen MA; Tuuminen R; Kärpänen T; Wu Y; Pytowski B; Koskinen PK; Ylä-Herttuala S; Alitalo K; Lemström KB
Circulation; 2010 Mar; 121(12):1413-22. PubMed ID: 20231530
[TBL] [Abstract][Full Text] [Related]
16. VEGFR signaling during lymphatic vascular development: From progenitor cells to functional vessels.
Secker GA; Harvey NL
Dev Dyn; 2015 Mar; 244(3):323-31. PubMed ID: 25399804
[TBL] [Abstract][Full Text] [Related]
17. Neuropilin-2 contributes to LPS-induced corneal inflammatory lymphangiogenesis.
Tang X; Sun J; Du L; Du H; Wang L; Mai J; Zhang F; Liu P
Exp Eye Res; 2016 Feb; 143():110-9. PubMed ID: 26500194
[TBL] [Abstract][Full Text] [Related]
18. VEGF-C and VEGF-C156S in the pro-lymphangiogenic growth factor therapy of lymphedema: a large animal study.
Visuri MT; Honkonen KM; Hartiala P; Tervala TV; Halonen PJ; Junkkari H; Knuutinen N; Ylä-Herttuala S; Alitalo KK; Saarikko AM
Angiogenesis; 2015 Jul; 18(3):313-26. PubMed ID: 26018927
[TBL] [Abstract][Full Text] [Related]
19. Molecular control of lymphatic metastasis.
Achen MG; Stacker SA
Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
[TBL] [Abstract][Full Text] [Related]
20. Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation.
Karpanen T; Wirzenius M; Mäkinen T; Veikkola T; Haisma HJ; Achen MG; Stacker SA; Pytowski B; Ylä-Herttuala S; Alitalo K
Am J Pathol; 2006 Aug; 169(2):708-18. PubMed ID: 16877368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
